Facebook Developing Slingshot against Rival Snapchat and Pfizer Rejected again by AstraZeneca
Facebook, Inc. (NASDAQ: FB) is developing an app similar to Snapchat called Slingshot, according to the Financial Times. The Financial Times says Slingshot will let users send short video messages with just a couple of taps on the screen. Last year Facebook failed to acquire SnapChat and had a $3B offer turned down. In an effort to have its own "ephemeral messaging" app, Facebook is developing Slingshot. CEO Mark Zuckerberg is reportedly supervising the development and it could be released later this month.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications. The companys products include Facebook mobile app and Website that enable people to connect, share, discover, and communicate with each other on mobile devices and personal computers; Messenger, a mobile-to-mobile messaging application available on iOS and Android phones; and Instagram, a mobile app and Website that enable people to take photos or videos, customize them with filter effects, and share them with friends and followers in a photo feed or send them directly to friends.
Get more information on Facebook, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/FB
TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.
Pfizer Inc. (NYSE: PFE) has updated their bid for AstraZeneca to $119B, only to be turned down again by AstraZeneca's board. The board noted in a statement that it "reiterates its confidence in AstraZeneca's ability to deliver on its prospects as an independent, science led business." Pfizer has said it won't raise its offer again or launch a hostile takeover bid over the heads of AstraZeneca's board.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. The companys Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimers disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation.
Get more information on Pfizer Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/PFE
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
Tags: